Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Evans T.R.J.Kudo M.Finn R.S.Han K.-H.ANN-LII CHENGIkeda M.Kraljevic S.Ren M.Dutcus C.E.Piscaglia F.Sung M.W.2021-08-312021-08-3120190007-0920https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069924178&doi=10.1038%2fs41416-019-0534-2&partnerID=40&md5=73213eb7615a483299576b973fcb7eb3https://scholars.lib.ntu.edu.tw/handle/123456789/580046This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper. ? 2019, The Author(s).[SDGs]SDG3erratumCorrection: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)erratum10.1038/s41416-019-0534-2313631702-s2.0-85069924178